In 1996, while the aesthetic laser industry raced to market, Aerolase made an unconventional choice we chose to be right,not first. The prevailing laser platforms of the era shared a fundamental limitation: they could not safely and effectively treat the full spectrum of Fitzpatrick skin types. Rather than accept that compromise. Aerolase’s founders committed to engineering a solution from the ground up.
Three decades later, that decision has defined not just a company but an entirely new standard of care. Today, Aerolase’s microsecond pulse technology powers treatments across more than 70 countries and counting, delivering clinically proven outcomes for more than 36 FDA-cleared indications, safely and effectively across all Fitzpatrick skin types.
THE ORIGIN: ENGINEERING EQUITY INTO THE LASER
The laser industry had a skin tone problem. Conventional millisecond pulse durations generated excessive thermal diffusion, creating unacceptable risks of hyperpigmentation, burns, and scarring for patients with darker skin. Aerolase spent nearly a decade isolating the precise energy delivery parameters that would change this equation.
The result was the 650-microsecond Nd:YAG laser platform, a pulse duration engineered in the critical window between nanosecond and millisecond domains. This wasn’t an incremental refinement It was a fundamental rethinking of how laser energy interacts With tissue, achieving selective photothermolysis with dramatically reduced epidermal damage and virtually no risk of post-inflammatory hyperpigmentation.
Aerolase earned its FDA 510(k) clearance in 2000 and expanded its regulatory portfolio through 2004, establishing the Light Pod Neo and Light Pod Era platforms that would form the foundation for the Neo Elite and Era Elite devices used by practitioners worldwide today 2015, the clinical foundation was complete, and a medical advisory board of leading dermatologists was in place, all before large-scale commercialization.
THE TECHNOLOGY: TWO WAVELENGTHS, LIMITLESS POSSIBILITIES
Aerolase’s clinical versatility stems from two complementary laser platforms, each engineered with the same philosophy of precision energy delivery. The Neo Elite features a 650-microsecond 1064nm Nd:YAG laser optimized for deep dermal and vascular targets, while the Era Elite delivers a 300-microsecond 2940nm Er:YAG laser for controlled full-ablative resurfacing Together, they address a comprehensive range of Clinical indication:
Delivered through a contact-free handpiece, requiring no consumables, no anesthesia, and minimal downtime, Aerolase has redefined what a laser platform can accomplish in a clinical setting Skin health professionals can treat a wide patient population with confidence, regardless of skin type, within a streamlined workflow.
PROVING IT GLOBALLY: INTENTIONAL EXPANSION, UNDENIABLE RESULTS
Between 2006 and 2015, industry-leading dermatologists across the United States, including Michael Gold, MD, and David Goldberg. MD adopted the platform and conducted independent case studies that validated clinical outcomes across diverse patient populations. International distributors followed, drawn by published clinical results.
Aerolase’s trajectory from technology pioneer to global market presence has been built on a principle that remains unchanged every adoption is a proof point, and every proof point is earned With the science validated globally, Aerolase turned its focus to building the commercial infrastructure worthy of its technology. The Neo Elite and Era Elite platforms launched in 2018, followed by the addition of the Exci308 excimer device in 2022, extending its reach into targeted phototherapy for autoimmune skin conditions like vitiligo and psoriasis.
THE NEXT 30 YEARS: WHERE PRECISION MEETS GLOBAL IMPACT
The aesthetic and medical laser market is projected to exceed $25 billion globally within the next decade1. And by 2050, it is projected that over 85% of the world’s population will have skin of color2. As the industry scales, so does the imperative for technology that serves all patients equally Aerolase is positioned at the center of that shift.
Aerolase’s commitment to treating all skin types safely isn’t a marketing position; it’s an engineering principle embedded in every device Aerolase has ever built. As global demographics shift and patient populations become increasingly diverse, that principle becomes not just a differentiator, but a necessity.
Thirty years ago, Aerolase set out to solve a problem the rest of the industry accepted as inevitable.
The next thirty years will be defined by the same principles that shaped the first: precision engineering clinical integrity, and an unwavering belief that the best technology should work for everyone.
The Science Comes First
The laser industry had a skin tone problem. We spent nearly a decade solving it-engineering 650-micropulse pulse technology that made safe treatments across all Fitzpatrick skin types possible for the first time.
Proving it Works Everywhere
We didn’t chase volume-we chose our first customers as carefully as we’d Chosen our technology Clinical outcomes, not marketing budgets, drove adoption.
From technology pioneer to market leader
The science was undeniable. Now we built the commercial engine to match it
Proving what 30 years of precision enables
Three decades of physics first innovation. One unwavering content healthy energy that works for every patient, every time.
1. "Medical laser Market Size to Hit USO 27.15 Billion by 2035.∼ Precedence Research, Dec. 2024, www.precedenceresearch.com/medical-laser-market.
2. Campbell-Stephens, R. M. (2021). Educational leadership and the global majority: Decolonising narratives. Palgrave Macmillan. https://doi.org/10.1007/978-3-030-88282-2
Disclaimer:
The above paid-for content was produced by and posted on behalf of the Sponsor. Content provided is generated solely by the Sponsor or its affiliates, and it is the Sponsor’s responsibility for the accuracy, completeness and validity of all information included. Cosmetics & Toiletries takes steps to ensure that you will not confuse sponsored content with content produced by Cosmetics & Toiletries and governed by its editorial policy.
